HOME >> MEDICINE >> NEWS
UI-led study indicates surgery is the best treatment for severe Bell's palsy paralysis

IOWA CITY, Iowa -- How to best treat patients with Bell's palsy who are at high risk of permanent loss of facial muscle control has remained a controversial subject among physicians for decades. However, results of a 15-year study led by University of Iowa Health Care researchers may help to finally settle the debate.

"We hope these findings will help change the attitudes of a lot of different people," said Bruce Gantz, M.D., UI professor and head of otolaryngology.

Timing and strategy are critical when it comes to the subgroup of patients with Bell's palsy who are at the greatest risks for permanent damage. The study results indicate that identifying this patient population and their subsequent surgical treatment must occur within two weeks of the onset of paralysis.

"If we are going to have any impact, the surgery has to come within the first two weeks," Gantz stressed.

Bell's palsy is partial or complete facial muscle paralysis resulting from a certain dysfunctional cranial nerve that is believed to be damaged by the herpes simplex virus type I. The condition affects about 40,000 Americans per year. Although medication will help most individuals fully or almost fully recover from Bell's palsy paralysis, about 10 to 15 percent of patients will not recover unless additional measures are taken.

The study had three related goals, all attempting to answer the primary questions troubling many clinicians treating patients with Bell's palsy. The researchers wanted to determine how to best identify which patients will be left with poor outcomes, establish whether surgical decompression might improve these patients' chances of recovery, and finally, figure out what, if any, impact time had on treatment.

The study results were based on patient outcomes of individuals with Bell's palsy treated at the UI Hospitals and Clinics, the University of Michigan and the Baylor College of Medicine.

Through their investigation, the UI-led team determin
'"/>

Contact: Jennifer Cronin
jennifer-cronin@uiowa.edu
319-335-9917
University of Iowa
14-Oct-1999


Page: 1 2 3

Related medicine news :

1. UI-led study shows experimental anti-cancer drug also has anti-HIV properties
2. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
3. UMaine study looks at infants and chronic nighttime crying
4. Chronic pain treatments more effective when taken together, new study shows
5. UNC study: Most N.C. family practitioners engage in unrecognized community service
6. New study in Nature demonstrates protection against cell death during heart attack
7. UCSF study offers insight into human circadian rhythms
8. International breast cancer prevention study launches in the United States and Canada
9. UW study shows blacks and Latinos are more satisfied with physicians of the same race
10. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
11. Advertising by academic medical centers may risk eroding public trust, says study

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: